about
Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumabGeneration of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during InflammationFlavonoids as Cytokine Modulators: A Possible Therapy for Inflammation-Related DiseasesThe expanding role of immunopharmacology: IUPHAR Review 16Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitorsMCP-1-induced protein-1, an immune regulatorThe structure of human interleukin-11 reveals receptor-binding site features and structural differences from interleukin-6The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors.The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics.Lacrimal gland-derived IL-22 regulates IL-17-mediated ocular mucosal inflammation.Involvement of NF-κB/IL-6 Pathway in the Processing of Colorectal Carcinogenesis in Colitis MiceIL-6 in diabetes and cardiovascular complications.Near-term anti-CD25 monoclonal antibody administration protects murine liver from ischemia-reperfusion injury due to reduced numbers of CD4+ T cellsBlockade of IL-6 Trans signaling attenuates pulmonary fibrosisIL-6 in inflammation, immunity, and diseaseEfficacy and safety of mavrilimumab in subjects with rheumatoid arthritisIn search of magic bullets: the golden age of immunotherapeutics.A gp130-Src-YAP module links inflammation to epithelial regeneration.Hepcidin expression in psoriasis patientsEfficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusionCannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritisMicroRNA-22 impairs anti-tumor ability of dendritic cells by targeting p38.CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis.Management of rheumatoid arthritis in People's Republic of China - focus on tocilizumab and patient considerationsInterleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension.Active immunization with Tocilizumab mimotopes induces specific immune responses.Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization.Interleukin-6 Deficiency Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutation.Gyeji-tang water extract exerts anti-inflammatory activity through inhibition of ERK and NF-κB pathways in lipopolysaccharide-stimulated RAW 264.7 cellsTargeting inflammation in emerging therapies for genetic retinal diseaseAccelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditionsThe enigmatic cytokine oncostatin m and roles in diseaseTh17-associated cytokines as a therapeutic target for steroid-insensitive asthmaInterleukin 6 and rheumatoid arthritisInterleukin-6 promotes tumor progression in colitis-associated colorectal cancer through HIF-1α regulation.Death domain-associated protein 6 (Daxx) selectively represses IL-6 transcription through histone deacetylase 1 (HDAC1)-mediated histone deacetylation in macrophagesEfficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study.
P2860
Q24598109-1F71EBC8-7638-4CEF-82F5-499EDF6DCDA1Q26738992-8149E98E-DC57-4A49-9E7B-9AB68E6391EEQ26746303-C665BEAF-FF2B-40BF-B5CA-5B72D5217E1DQ26801862-27E1B5C1-1CCF-4B82-928E-47E514AC4D49Q26824970-AF17A2BB-2142-4161-AF26-16500887FCD0Q26993217-720D7BDC-D7DE-4E67-9D84-0278EE7D36F5Q27695574-E8953B1D-261C-4955-AD89-A303EB23180FQ30486741-CFDCD3D7-363E-4346-8140-1DDE9C27A531Q30566003-B33E2B85-2BF3-4D0E-8F39-00D70F301254Q33870377-695927E2-ADC8-4183-B5E9-05EA54F869C9Q33908674-B114F077-B6D3-4B23-81A4-D1AFF7C98AE0Q34025142-CB4938B9-2960-46FA-ABBC-39BED7C82773Q34134224-A2E5E5DE-9A44-40A9-8F96-F76133D0E51FQ34218604-40760C71-3415-4F2E-A428-CA4D2CC41BA1Q34248105-AA76B029-862D-48F6-885B-0456C6EFFABDQ34317197-6F65BFFD-C85D-46DB-ACA6-BF310C6FEDB6Q34356481-4D7C3E08-8138-489D-AFE2-D79591DCF3F1Q34465259-E0D01130-66B2-4EFF-A833-6F8CA9529DB0Q34591625-89AC5BEB-4D7D-4800-8E7B-F9378E7FC06BQ34646212-8D59F0A8-DACE-4CEA-B19A-BD469F58BCBCQ34674172-1E7A55EA-A96E-4968-A699-182AF22E428FQ34826956-DD3F6B06-52D1-4279-AC66-7429D61E5382Q35223319-59D1248A-8496-43F0-9361-ED0D7744FE6CQ35234933-79ABC8CA-054F-4E42-A99F-7952492FCEEDQ35555943-F25845BE-AF5C-4D0B-9562-2793AEB07105Q35618458-4B3869F0-CC97-4DBC-A206-3DF7BC8F3678Q35644609-576E14DC-E7AB-4C8F-894B-57E4C2FB273FQ35649177-B3FB1EE2-A775-4786-AACA-139EFCD26891Q35724900-D6264D52-13F0-431C-90B9-77069C576A19Q35818087-FC8FC78C-B32F-40F4-B0C5-89FD7700E9C2Q35986943-270129A8-2C5C-4561-AEB1-A547DB404CC6Q36161919-611EF1D3-2AE3-49BA-A1E0-D820C3C362F1Q36676772-F0894F9F-103A-43C0-8939-71D617CAFF2EQ36746012-387B88AE-F664-4876-9F83-45B48BDAB399Q37409222-7403725A-C3DB-4CEB-96D7-4359741F9EE3Q37456949-1773B782-24E9-423E-95E6-EAFAE56CF232Q37553940-40004A30-1C3F-4519-A1C1-320DDF7636EEQ37582274-77CE7340-7F5E-44D9-9C6E-93E7350A76C9Q37691616-7F793840-3258-4BA3-BDF4-56A54A655ACCQ37725870-FC9869D4-E25A-492C-9E54-3677357D5EEE
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Therapeutic targeting of the interleukin-6 receptor.
@en
Therapeutic targeting of the interleukin-6 receptor.
@nl
type
label
Therapeutic targeting of the interleukin-6 receptor.
@en
Therapeutic targeting of the interleukin-6 receptor.
@nl
prefLabel
Therapeutic targeting of the interleukin-6 receptor.
@en
Therapeutic targeting of the interleukin-6 receptor.
@nl
P1476
Therapeutic targeting of the interleukin-6 receptor
@en
P2093
Tadamitsu Kishimoto
Toshio Tanaka
P304
P356
10.1146/ANNUREV-PHARMTOX-010611-134715
P577
2011-09-09T00:00:00Z